Who Owns MacroGenics Company?

Who owns MacroGenics today?

MacroGenics went public on October 10, 2013, after raising $80,000,000, shifting control from venture backers to public and institutional investors. Its ownership mix affects R&D priorities, governance, and long-term clinical strategy.

Major shareholders include institutional investors, mutual funds, and biotech-focused funds, while insiders and founders retain meaningful stakes, shaping product and pipeline decisions. See MacroGenics Porter's Five Forces Analysis for strategic context.

Founders and Early Ownership of MacroGenics trace to a small group of scientists and biotech executives led by Scott Koenig, Jeffrey S. Himawan, and Peter S. Kies; initial equity was concentrated among founders and early venture partners who financed development of the DART platform.

Founding team

Scott Koenig (President and CEO since 2001), Jeffrey S. Himawan, and Peter S. Kies were core founders who combined scientific, strategic and financial expertise.

Early leadership roles

Koenig brought experience from MedImmune and Synagis development; Kies served as CFO providing financial scaffolding; Himawan connected venture capital expertise.

Initial capitalization

Series A–E rounds collectively raised over $150,000,000 to support antibody engineering and oncology programs.

Key investors

Major early backers included OrbiMed Advisors, Essex Woodlands, InterWest Partners, and RiverVest Venture Partners, which together held a majority stake in the first decade.

Ownership structure

Standard founder vesting and investor preferred share classes were used to align incentives and preserve investor control until clinical milestones were met.

Balance of power

The concentration of venture capital ownership meant strategic direction was regularly calibrated against institutional investors' clinical and financial milestones.

Early ownership and financing laid the foundation for later public markets activity and institutional investor participation in MacroGenics' corporate structure.

Founders and investor highlights

Key facts about early founders and ownership stakes, relevant to MacroGenics ownership and investor questions.

• Founders: Scott Koenig (CEO), Jeffrey S. Himawan, Peter S. Kies
• Early VC backers: OrbiMed, Essex Woodlands, InterWest, RiverVest
• Series A–E funding exceeded $150,000,000
• Early investor group held majority stakes through first decade

For more on governance and strategic growth tied to these founding investments, see Growth Strategy of MacroGenics

Complete MacroGenics Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Key events reshaping MacroGenics ownership include the 2013 IPO, progressive secondary offerings and insider sales, and the steady transfer of shares from venture capital to institutional and index fund managers through 2024–2025.

The public ownership concentration accelerated after the IPO, and by late 2024 institutional ownership reached approximately 88%, reflecting MacroGenics ownership becoming a component of many healthcare and broad-market portfolios.

Major stakeholders and stake sizes

MacroGenics investors are dominated by large passive and active asset managers, with concentrated positions among the top holders and modest insider stakes.

• Vanguard Group — approximately 9.5% of outstanding shares
• BlackRock Inc. — roughly 7.2%
• State Street Corporation — top-5 institutional holder (approximate mid-single-digit percent)
• RA Capital Management and specialized healthcare funds — active, variable positions tied to clinical readouts

Insider ownership, including CEO Scott Koenig and other executive officers, totals about 3–4%, while the shift from venture capital to institutional and index fund control has oriented company strategy toward near-term clinical milestones and regulatory progress for assets such as vobaroniglerene; see the Marketing Strategy of MacroGenics for related analysis.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

MacroGenics' board is chaired by Scott Koenig and includes independent directors such as Scott Jackson, Karen Ferrante, and Stephen Evans-Freke, combining clinical development expertise and financial oversight to reflect the company's institutional investor base and scientific roots.

The board majority consists of non-executive directors to ensure independent oversight of management during costly Phase 2 and Phase 3 trials for lead oncology candidates; major institutional shareholders such as Vanguard and BlackRock influence shareholder votes under the company's one-share-one-vote structure.

Board composition and voting power

The board balances scientific leadership with investor-focused governance; voting follows a one-share-one-vote model, giving large institutions measurable sway.

• Major institutional investors: Vanguard and BlackRock hold significant stakes and voting influence
• Majority independent directors provide checks on executive decisions during clinical spend
• No recent successful activist interventions or proxy battles reported through 2025 filings
• Refer to Revenue Streams & Business Model of MacroGenics for additional corporate context

MacroGenics Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

MacroGenics ownership shifted notably from 2023–2025 as clinical readouts and funding needs reshaped the shareholder base; institutional healthcare investors increased their stake while short-term traders and hedge funds rotated in response to TAMARACK data and secondary offerings.

Data from the TAMARACK study of vobaroniglerene drove turnover among hedge funds and retail holders; management prioritized capital raises to support DART and TRIDENT programs while signaling continued independence amid market consolidation speculation.

Institutional concentration

Healthcare-specific funds increased positions, raising stability; the largest mutual and pension funds together held a majority of shares by early 2025.

Shareholder turnover

Positive or mixed TAMARACK readouts triggered spikes in trading volume and shifts in ownership composition among hedge funds and short-term traders.

Capital strategy

Secondary offerings in 2023–2024 diluted shares but secured $220M to fund trials and extend the cash runway into 2026.

Acquisition prospects

Industry consolidation and the company’s antibody platforms made MacroGenics a visible target; no public acquisition offers were announced as of early 2025. Read a Brief History of MacroGenics for context on corporate evolution.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE